Ozempic Gastroparesis Settlement Criteria Explained

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Awareness to Targeted Drug Safety

For decades, the general health and science information landscape has guided public understanding of wellness, disease prevention, and the safe use of medications. This foundational knowledge has helped individuals navigate common health concerns, from nutrition to chronic condition management. Within this broad context, the public has learned to weigh benefits and risks associated with therapeutic interventions, including prescription drugs. As medical science advances, new questions arise about the long-term effects of widely used treatments. One such area of emerging focus involves medications originally developed for metabolic conditions, such as GLP-1 receptor agonists. These drugs have been prescribed to millions, yet reports of gastrointestinal side effects have prompted closer scrutiny. Specifically, cases of gastroparesis—a condition characterized by delayed stomach emptying—have been linked to exposure to these agents. This shift from general health awareness to a more targeted concern reflects a natural progression in medical discourse. The transition from broad health education to specific drug-safety considerations now leads us to examine the legal and clinical criteria surrounding Ozempic-related gastroparesis settlements. Understanding these criteria requires a careful look at exposure history, symptom documentation, and the evolving standards for compensation in such cases.

Understanding Ozempic and Its Gastrointestinal Risks

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, and to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes and established cardiovascular disease (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, its use has been associated with a range of gastrointestinal adverse reactions, including gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction. Gastroparesis presents clinically with symptoms such as nausea, vomiting, early satiety, bloating, and abdominal pain, and can lead to malnutrition, dehydration, and impaired quality of life. Diagnosis typically involves gastric emptying scintigraphy or breath tests, and management often includes dietary modifications, prokinetic agents, and antiemetics. Clinical trial data from the Ozempic prescribing information indicate that gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo. In the pool of placebo-controlled trials, gastrointestinal adverse reactions were reported in 15.3% of placebo patients, 32.7% of those on Ozempic 0.5 mg, and 36.4% of those on Ozempic 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions compared to placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In a trial comparing Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently with the 2 mg dose (34.0%) versus the 1 mg dose (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these tables, the spectrum of reported gastrointestinal symptoms—particularly nausea, vomiting, dyspepsia, and gastroesophageal reflux—overlaps with the clinical presentation of gastroparesis.

Mechanistic Pathways and Risk Factors

The mechanistic pathways linking Ozempic to gastroparesis involve the drug's action as a GLP-1 receptor agonist. GLP-1 receptors are expressed in the gastrointestinal tract, and activation of these receptors slows gastric emptying, which is part of the drug's intended effect on postprandial glucose regulation. However, excessive or prolonged slowing of gastric emptying can lead to symptomatic gastroparesis. The risk appears to be dose-dependent, as evidenced by higher rates of gastrointestinal adverse reactions at higher doses (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The timeline between exposure and documented harm is variable; symptoms often emerge during dose escalation, but some patients may develop persistent gastroparesis even after dose stabilization. From a risk perspective, the adequacy of warnings regarding Ozempic and gastroparesis is a critical consideration. The prescribing information includes warnings about gastrointestinal adverse reactions, but does not specifically mention gastroparesis as a distinct adverse event. This may leave patients and healthcare providers unaware of the potential for this serious condition.

Settlement Criteria and Legal Considerations

For affected patients, settlement-related considerations hinge on establishing a causal link between Ozempic use and the development of gastroparesis, as well as documenting the timeline of exposure and symptom onset. Key factors include the presence of gastrointestinal symptoms during or after Ozempic use, the exclusion of other causes of gastroparesis (such as diabetes-related autonomic neuropathy, which is common in the patient population for whom Ozempic is indicated), and the temporal relationship between drug initiation and symptom development. Patients who experienced severe or persistent gastroparesis leading to hospitalization, nutritional deficiencies, or significant disability may have stronger claims. In summary, while Ozempic is effective for glycemic control and cardiovascular risk reduction, its use is associated with a dose-dependent increase in gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The mechanistic basis for this effect is well-established, and the clinical trial data provide evidence of the frequency and severity of these reactions. Patients who develop gastroparesis after starting Ozempic should seek medical evaluation and consider legal consultation to assess their eligibility for settlement, particularly if the drug's labeling did not adequately warn of this risk.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Ozempic and gastroparesis?

Ozempic (semaglutide) is a GLP-1 receptor agonist that slows gastric emptying as part of its mechanism. This can lead to symptomatic gastroparesis, especially at higher doses. Clinical trials show increased gastrointestinal adverse reactions, including nausea, vomiting, and dyspepsia, which overlap with gastroparesis symptoms (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

What are the criteria for an Ozempic gastroparesis settlement?

Settlement criteria typically require documented Ozempic exposure, a confirmed gastroparesis diagnosis via gastric emptying scintigraphy or breath tests, exclusion of other causes (e.g., diabetic autonomic neuropathy), and a temporal relationship between drug initiation and symptom onset. Severe cases leading to hospitalization or disability may strengthen claims.

How common are gastrointestinal side effects with Ozempic?

In placebo-controlled trials, gastrointestinal adverse reactions occurred in 15.3% of placebo patients, 32.7% on Ozempic 0.5 mg, and 36.4% on Ozempic 1 mg. Discontinuation due to GI issues was 0.4% for placebo, 3.1% for 0.5 mg, and 3.8% for 1 mg (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

Ozempic Prescribing Information - DailyMed

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.